Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sebelipase alfa in children with LAL Deficiency
NCT01371825Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2011
- Primary completion
- Jan 2018
- Modality
- Replacement Enzymes
- Countries
- 5
01
Overview
A Phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency (LALD), Wolman disease, sponsored by Alexion Pharmaceuticals. Started May 2011; status: completed.
02
Drugs
sebelipase alfa
03
Conditions
lysosomal acid lipase deficiency (LALD)Wolman disease
Beyond the preview
Go deeper on NCT01371825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01371825.